An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)
CompletedOBSERVATIONAL
Enrollment
52
Participants
Timeline
Start Date
July 31, 2012
Primary Completion Date
August 31, 2013
Study Completion Date
August 31, 2013
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Trial Locations (1)
26121
Oldenburg
All Listed Sponsors
lead
Hoffmann-La Roche
INDUSTRY
NCT01790217 - An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC) | Biotech Hunter | Biotech Hunter